Cargando…
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
BACKGROUND: Venous thromboembolism is a common complication of cancer and its treatments. Treatment of cancer-associated thrombosis (CAT) differs from treatment of thrombosis in noncancer patients, requiring a daily injection of low-molecular-weight heparin (LMWH) for 6 months instead of an oral ant...
Autores principales: | Seaman, Siwan, Nelson, Annmarie, Noble, Simon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986276/ https://www.ncbi.nlm.nih.gov/pubmed/24748774 http://dx.doi.org/10.2147/PPA.S58595 |
Ejemplares similares
-
Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study
por: Noble, Simon, et al.
Publicado: (2015) -
Patient Experience of Living With Cancer‐Associated Thrombosis in Canada (PELICANADA)
por: Noble, Simon, et al.
Publicado: (2019) -
The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015) -
Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review
por: Fioretti, Agnese Maria, et al.
Publicado: (2022) -
Safety and Feasibility of Subcutaneous Low Molecular Weight Heparin for Cerebral Venous Sinus Thrombosis
por: Kim, Ji Seon, et al.
Publicado: (2005)